Charles Schwab Investment Management Inc. Purchases 43,635 Shares of Iradimed Corporation (NASDAQ:IRMD)

Charles Schwab Investment Management Inc. raised its position in Iradimed Corporation (NASDAQ:IRMD) by 189.7% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 66,632 shares of the medical equipment provider’s stock after purchasing an additional 43,635 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Iradimed were worth $3,351,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the company. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Iradimed by 54.3% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 13,385 shares of the medical equipment provider’s stock worth $673,000 after acquiring an additional 4,708 shares during the period. Quest Partners LLC grew its position in Iradimed by 32.9% during the third quarter. Quest Partners LLC now owns 13,071 shares of the medical equipment provider’s stock valued at $657,000 after buying an additional 3,236 shares during the period. Gladius Capital Management LP increased its holdings in Iradimed by 126.6% during the third quarter. Gladius Capital Management LP now owns 1,727 shares of the medical equipment provider’s stock worth $87,000 after buying an additional 965 shares during the last quarter. Huntington National Bank boosted its stake in Iradimed by 51.3% in the third quarter. Huntington National Bank now owns 1,487 shares of the medical equipment provider’s stock valued at $75,000 after acquiring an additional 504 shares during the last quarter. Finally, Principal Financial Group Inc. bought a new position in shares of Iradimed during the 3rd quarter valued at approximately $246,000. Institutional investors own 92.34% of the company’s stock.

Iradimed Price Performance

Shares of IRMD opened at $52.63 on Friday. Iradimed Corporation has a 1 year low of $40.18 and a 1 year high of $57.95. The stock’s fifty day moving average price is $52.58 and its two-hundred day moving average price is $47.96. The firm has a market cap of $666.82 million, a PE ratio of 36.05 and a beta of 0.82.

Iradimed Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, November 25th. Stockholders of record on Friday, November 15th were paid a $0.15 dividend. The ex-dividend date was Friday, November 15th. This represents a $0.60 annualized dividend and a dividend yield of 1.14%. Iradimed’s payout ratio is 41.10%.

Insider Activity

In other Iradimed news, CFO John Glenn sold 2,500 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $54.18, for a total transaction of $135,450.00. Following the sale, the chief financial officer now owns 4,383 shares of the company’s stock, valued at $237,470.94. The trade was a 36.32 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 37.10% of the company’s stock.

Iradimed Company Profile

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.